Eli Lilly scores positive phase III results with new eczema treatment

From a total of five phase III trials involving drug candidate lebrikizumab treating atopic dermatitis, three studies have produced positive results.
Photo: MIKE SEGAR/REUTERS / X90033
Photo: MIKE SEGAR/REUTERS / X90033
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL FRANK CHRISTENSEN

While Sanofil continues to triumph with eczema drug Dupixent, with Leo Pharma also working to launch its medicament, Adtralza, targeting the skin disease, both in the EU and US, Eli Lilly now moves closer to the finish line with its treatment candidate.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading